- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol...
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron PR Newswire MENLO PARK, Calif., Aug. 5, 2020 MENLO PARK, Calif., Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent...
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform - TrialSpark's integrated tech platform and trial model will enable resTORbio to...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind...
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and VSLR Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, July 24, 2020 NEW YORK, July 24, 2020 /PRNewswire/ -- If...
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and GCAP Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, July 10, 2020 NEW YORK, July 10, 2020 /PRNewswire/ -- If...
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.